Evaxion Biotech AS (EVAX)
4.05
-0.12
(-2.88%)
USD |
NASDAQ |
May 01, 16:00
4.05
0.00 (0.00%)
After-Hours: 20:00
Evaxion Biotech Shareholders Equity (Quarterly): -4.739M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.739M |
| September 30, 2023 | -89.76M |
| June 30, 2023 | 2.535M |
| March 31, 2023 | -78.72M |
| December 31, 2022 | 8.303M |
| September 30, 2022 | -65.76M |
| June 30, 2022 | 20.15M |
| March 31, 2022 | 26.39M |
| Date | Value |
|---|---|
| December 31, 2021 | 32.44M |
| September 30, 2021 | 16.65M |
| June 30, 2021 | 21.83M |
| March 31, 2021 | 27.80M |
| December 31, 2020 | 7.038M |
| September 30, 2020 | 7.903M |
| December 31, 2019 | 9.362M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-89.76M
Minimum
Sep 2023
32.44M
Maximum
Dec 2021
-3.906M
Average
8.303M
Median
Dec 2022
Shareholders Equity (Quarterly) Benchmarks
| Ascendis Pharma A/S | -161.05M |
| DBV Technologies SA | 140.19M |
| Cellectis SA | 76.12M |
| Adaptimmune Therapeutics PLC | 39.51M |
| Akari Therapeutics PLC | -0.229M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 12.89M |
| Total Liabilities (Quarterly) | 17.63M |
| Debt to Equity Ratio | -1.825 |
| Current Ratio | 1.179 |